Skip to main content

Table 4 ECG summary parameters (means in ms) for day 1, day 3 pre-dose, day 3 post-dose and day 7 for treatment with three doses of Eurartesim® [N = 1,002] based on central laboratory readings

From: Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania

  PR HR QT QTcB QTcF 95% *Confidence interval *P-value
Visit        
Day 1 (baseline) 134. 2 104. 6 331. 9 429. 6 393. 3 - -
Day 3 pre-dose 3 138. 3 92. 5 355. 4 434. 2 411. 2 - -
Day 3 post-dose 3 140. 5 91. 6 366. 1 444. 1 415. 8 - -
Day 7 137. 6 94. 2 346. 2 428. 2 398. 6 - -
Δ Days 1 to 3 pre-dose 4. 1 −12. 1 23. 5 4. 6 17. 9 16 ,19 <0. 001
Δ Days 1 to 3 post-dose 6. 3 −13. 1 34. 2 14. 6 22. 5 21,24 <0. 001
Δ Days 1 to 7 3. 3 −10. 3 14. 2 -. 31 5. 3 4,7 <0. 001
  1. *Confidence intervals and *P-values were calculated for the mean change in QTcF.